Douglas Johnson
Latest Articles
AcelRx Will Go It Alone With Dsuvia, But The Future Looks Bright
Hopes Are High For AcelRx After Dsuvia Approval - Will Price Follow?
Clarifying The Recent Storm Of News Related To AcelRx's Dsuvia
Expected Value Investing:  Analyzing Genfit's Huge Potential
AcelRx Will Overcome Its Recent Stock Woes
Expected Value Investing:  The Case Against Galmed
Expected Value Investing: Diving Deeper On Conatus
Breaking Down The NASH Cirrhosis Market - Gilead Poised For Success, But Is It Enough To Boost Stock Price?
AcelRx Finally Has An AdCom Date. Time For A Run Up?
Breaking Down The NASH Fibrosis Market - Intercept, Genfit Primed For Potential Market Dominance
Achaogen Continues To Slide - How Much Farther Can It Go?
scPharmaceuticals Still Trading Below Cash, But Future Is Unclear
AcelRx Provides Encouraging Q2 Update
After Recent CRL, scPharmaceuticals Is Trading Below Cash
Cheap AcelRx Options Minimize Risk And Maximize Potential Profit
AcelRx Sparks Investor Interest As It Gears Up For Another Shot With Dsuvia
Conatus Pharmaceuticals: A Long-Term Play In The Rapidly Expanding NASH Market
Roku:  An Overhyped Tech Stock Set To Suffer The Same Fate As Snap
Can Achaogen Turn It Around After A Long Slide?
After Heavy Losses, Can Antares Pharma Bounce Back?
Mitigating Potential Risk As Dynavax Run Slows
After Disappointing CRL For Dsuvia, What's Next For AcelRx?
AcelRx Remains An Attractive Buy After Strong Run